

Lung Cancer Presentations and Sites In Fiberoptic Bronchoscopy

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Chest Diseases and Tuberculosis*

Presented By

Hossam El-Din Helmy Abd Elmaogod

M.B., B.CH.

Faculty of Medicine, Cairo University

Under supervision of

Prof. Dr. Tarek Safwat

Professor of Chest Diseases

Faculty of Medicine - Ain Shams University

Dr. Haytham Samy Diab

Assistant Professor of Chest Diseases

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدقة الله العظيم

سورة البقرة الآية: ٣٢



*First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Tarek Safwat**, Professor of Chest Diseases Faculty of Medicine - Ain Shams University for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Haytham Samy Diab**, Assistant Professor of Chest Diseases Faculty of Medicine - Ain Shams University for his sincere efforts, fruitful encouragement.*

Hossam El-Din Helmy

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	ii
List of Abbreviations	iv
Introduction	1
Aim of the Work	4
Lung Cancer.....	5
Epidemiology.....	10
Pathogenesis of lung cancer	12
Etiology of lung cancer	14
Pathology and Classification	19
Clinical Presentation	24
Investigations	27
Staging of lung cancer	36
Management	41
Lung cancer screening.....	44
Bronchoscopy	45
Bronchopulmonary Segment	47
Types of bronchoscopy	50
Indications for Bronchoscopy	53
Complications of bronchoscopy	61
Subjects and methods.....	64
Results	69
Discussion.....	83
Summary and Conclusion.....	89
Recommendations	91
References	92
Arabic summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Occupational causes of lung cancer.....	16
Table (2):	2015 WHO Classification of Lung Tumor.	19
Table (3):	Two-stage system for small cell lung cancer	23
Table (4):	Range of frequencies of initial symptoms and signs of lung cancer:.....	24
Table (5):	Description of personal characteristics of studied patients	69
Table (6):	Description of hemoglobin level of studied patients	72
Table (7):	Description of comorbidities of studied patients.	73
Table (8):	Description of the location of the lesion of studied patients.....	74
Table (9):	Description of macroscopic bronchoscopic presentations during bronchoscopic procedure of the studied patients.	75
Table (10):	Description of histopathology of studied patients.	77
Table (11):	Relation between histopathological types of lung cancer and both of gender and smoking history.	78
Table (12):	Description of histopathology according to age	80
Table (13):	Relation between histopathological types of lung cancer and anatomical bronchoscopic locations of the lesions.	81
Table (14):	Relation between histopathological types of lung cancer and macroscopic bronchoscopic presentations.....	82

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Bronchopulmonary segments.....	49
Figure (2):	Abnormal finding in the white light mode (A). By NBI, the abrupt ending vessels and same loops are visible (B).	50
Figure (3):	Abnormal finding in the autofluorescence mode (A). In the NBI mode, atypical dotted vessels are visible (B).	52
Figure (4):	Description of sex among studied patients with lung cancer.	70
Figure (5):	Description of smoking history of studied patients.....	71
Figure (6):	Description of hemoglobin level of studied patients.....	72
Figure (7):	Description of comorbidities of studied patients	73
Figure (8):	Description of anatomical location of the lesion of the studied patients	74
Figure (9):	Description of macroscopic bronchoscopic presentations during bronchoscopic procedure of studied patients.....	76
Figure (10):	Description of histopathology of studied patients.....	77
Figure (11):	Description of histopathological types of lung cancer according to gender	79
Figure (12):	Description of histopathological types of lung cancer according to smoking.	79
Figure (13):	Description of histopathological types of lung cancer according to age.	80
Figure (14):.	Description of histopathological types of lung cancer according to anatomical bronchoscopic locations of the lesions.....	81

List of Figures cont...

Fig. No.	Title	Page No.
Figure (15):	Description of histopathological types of lung cancer According to macroscopic bronchoscopic presentations.....	82

List of Abbreviations

Abb.	Full term
ABG	Arterial blood gases
ACTH.....	Adenocorticotrophic hormona
AFI.....	Autofloresnce imaging
BAL.....	Bronchoalveolar lavage
BL	Bronchial lavage
CIS.....	Carcinoma in situ
COPD.....	Chronic obstructive pulmonary disease
CT	Computerized tomography
CXR.....	Chest x ray
DM	Diabetes mellitus
DNA.....	Deoxyribo nucleic acid
EBUS.....	Endobronchial ultrasound
ECG	Electro cardio gram
EGFR.....	Epidermal growth factor receptor
EML4-ALK... ..	Echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase
FOB.....	Fiber optic bronchoscope
Her2.....	Human Epidermal Growth Factor Receptor 2
HOA.....	Hypertrophy osteoarthropathy
LEMS.....	Lambart eaton myasthenia syndrome
LIFE.....	Light imaging fluorescent endoscopy
LMB.....	Left main bronchus
Mabs	Mono clonal antibodies
MRI.....	Magnetic resonance imaging
NBI.....	Narrow band inmaging
NBTE.....	Non bacterial thrombotic endocarditis
NSCLC.....	Non small cell lung cancer
PET.....	positron emission tomography
RMB.....	Right main bronchus
RPT.....	Randomized population trial
RULB.....	Right upper lobe bronchus
SAFE	System of auto fluorescence endoscopy
SCC.....	Squamous cell carcinoma

List of Abbreviations cont...

Abb.	Full term
<i>SCLC</i>	<i>Small cell lung cancer</i>
<i>SD</i>	<i>Standard deviation</i>
<i>SIADH</i>	<i>Syndrome of inappropriate antidiuretic hormone</i>
<i>SVGO</i>	<i>Superior vena cava obstruction</i>
<i>TB</i>	<i>Tuberculosis</i>
<i>TSG</i>	<i>Tumor suppressor gene</i>
<i>US</i>	<i>Ultra sound</i>
<i>VATS</i>	<i>Video-assisted thoracoscopic surgery</i>
<i>WHO</i>	<i>World health organization</i>
<i>WLB</i>	<i>White light bronchoscope</i>

Abstract

All the patients that diagnosed as non bronchogenic carcinoma was excluded from the study.

In addition to that the most affected site bronchoscopically were the upper lobes RULB which was affected in seven patients 19.44 % of cases, while LULB was affected in six patients (16.67%) of cases while lingual was not detected to be affected in any case had been studied.

The most common presentation by FOB was endobronchial lesion 25 patients represented 69.44% of cases, luminal narrowing 4 patients 11.11%, extraluminal compression 2 patients 5.56%, mucosal infiltrations one patient 2.78% and finally Mucosal infiltration combined with Luminal narrowing four patients 11.11%.

Keywords: *Mono clonal antibodies - Left main bronchus-
Bronchial lavage - Hypertrophy osteoarthropathy*

INTRODUCTION

Lung cancer as the most common cancer in the world represents a major public health problem. Worldwide it accounts for approximately 1.2 million cancer-related deaths each year. In men it is the largest cause of mortality, and in women it is the third largest cause, just after breast and intestinal cancer, but before cervical cancer. Good prevention and early detection of breast and cervical cancer mean that lung cancer will be the leading cause of mortality in women worldwide (*Liang et al., 2009*).

Tobacco causes 80-90% of lung cancer cases (*CR-UK CancerStats Monograph, 2004*). It is often stated that tobacco control measures are likely to be the most important single tool in decreasing lung cancer mortality. Yet, however effective such measures are, we will continue to have large numbers of cases in smokers and ex-smokers for some time to come. Non-tobacco related lung cancer deaths are also significant, killing more people every year in the UK than cervical cancer and melanoma combined. Research is therefore still needed to improve the outcomes for all lung cancer patients.

Symptoms do not usually occur until the cancer is advanced, and may include persistent cough, sputum streaked with blood, chest pain, voice change, worsening shortness of breath, and recurrent pneumonia or bronchitis (*Cancer Facts and Figures, 2015*).

Lung cancer is classified by its histologic appearance into small cell lung cancer (SCLC) or non–small cell lung cancer (NSCLC). NSCLC is divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma; these are further subclassified (*Travis et al., 2001*).

Flexible bronchoscopy is a well-established procedure in pulmonary medicine. It is considered an important tool in the diagnosis, staging, and the therapy of lung cancer and many other varieties of pulmonary diseases (*Ouellette, 2006*).

It is a procedure that enables the physician or surgeon to examine the major air passages of the lungs. This allows the physician to evaluate the lungs and take small samples of tissue or fluid, if necessary. Usually the procedure is performed after mild sedation and numbness of the nose or mouth. The physician will then insert a bronchoscope, which is a flexible lighted tube about the width of a pencil, through the nose or mouth and into the windpipe. A small channel in the instrument allows tissue and fluid samples to be collected when appropriate (*ACCP, 2004*).

More than 70% of lung carcinomas can be approached with FB and although the yield is dependent on operator's experience, a high level of diagnostic accuracy can be achieved by taking between three and five biopsy specimens and a combination of brushing, biopsy, and bronchial washes can

expect to establish a diagnosis in more than 60% of cases (*Mazzone et al., 2002*).

When the tumor is visible but is intramural rather than endobronchial in distribution the diagnostic yield falls to 55% and is reduced further when the tumor lies beyond the bronchoscopist's vision (*El-Bayoumi and Silvestri, 2008*).

AIM OF THE WORK

The aim of the this work is to detect the predominant bronchoscopic presentations and anatomical locations in all histopathological patterns of lung cancer.

LUNG CANCER

Lung cancers was uncommon before the advent of cigarette smoking it was not even recognized as a distinct disease until 1761 (*Herbst et al., 2008*).

Different aspects of lung cancer were described further in 1810 (*Bayle Gaspard, 1810*).

Malignant tumors made up only 1% of all cancers at autopsy in 1878, but have risen to 10-15% by early 1900s (*Witschi, 2001*). Case reports in the medical literature numbered only 374 worldwide in 1912 (*Adler, 1912*), but a review of autopsies showed the incidence of lung cancer had increased from 0.3% in 1852 to 5.66 in 1952 (*Grannis, 2007*). In Germany in 1929, physician Fritz Lickint recognized the link between smoking and lung cancer (*Witschi, 2001*), which led to an aggressive antismoking campaign (*Proctor, 2000*).

British Doctors' Study published in the 1950s, was the first solid epidemiological evidence of the link between lung cancer and smoking (*Doll and Hill, 1956*). As a result, in 1964 the Surgeon General of the United States Lung Cancer: Risk factors, management, And Prognosis recommended smokers should stop smoking (*US Department of Health Education and Welfare, 1964*). The connection between radongases was first recognized among miners in the Ore Mountains near Schneeberg, Sxony. Silver has been mined there since 1470,